Pune-based pharma major Emcure Pharmaceuticals Ltd. has ventured into the daily supplements segment by launching a more significant portfolio of its Arth brand. The company, further aiming to expand its footprint, has roped in Bollywood actress Vidya Balan as brand ambassador, hoping to create awareness and stimulate conversation on women’s health issues.
The new Arth range of products is launched specifically to counter issues of greatest concern to health, such as personal hygiene, sleeping properly, and staying mentally alert. Emcure’s tie-up with Vidya Balan signifies its commitment to empowering women through health-oriented choices.
“A household name recognized throughout the country, Vidya will discuss under-talked about yet important areas of health such as intimate care and sleep disorders, nudging women towards claiming control of and placing value upon their health,” said Emcure in an official release.
A Push for Wholistic Good Women’s Wellness
According to the tie-up, Vidya Balan will support three of the key products in the Arth portfolio:
- Intimate Care: A formula that helps in soothing itchiness and dryness in intimate parts.
- Sleep Support Gummies: Energized to give good and refreshing sleep.
- Brain Fog Aid: A supplement to help increase focus and brain function.
Talking about being excited, Vidya Balan said, “I am glad to be associated with Emcure’s Arth range—a brand that cares for and knows about women’s overall well-being. Women are the pillar of families and society, yet their health remains secondary. I appreciate Emcure’s commitment towards addressing the unique health issues of women and empowering them for self-care of their health. Good health comes first for the right empowerment, and through this relationship, I want to motivate and inspire women to self-priority through judicious decisions.”
Namita Thapar, Whole-time Director, Emcure Pharmaceuticals Ltd., said that Vidya Balan was the ideal fit for the brand’s vision. “We are thrilled to be associated with Vidya, who is fearless, genuine, and embodies the spirit of our brand. She is a staunch supporter of women’s well-being and is never afraid to speak on any topic. We’re looking forward to collaborating with her to discuss and demystify issues related to women’s health that are generally considered taboo,” she added.
Emcure’s Financial and Market Performance
Emcure Pharmaceuticals enjoys a strong presence in the Indian Pharmaceutical Market (IPM), which is operated by Emcure India and Zuventus Healthcare. As of March 2024, it had a market share of 2.78%, placing it among India’s top 15 pharmaceutical players.
Financial Highlights:
- Revenue Growth: The company’s operating income grew by 11.2% year-on-year in FY24 to ₹66,583 million from ₹59,858 million in FY23.
- Operating Profit: While revenue growth did happen, operating profit margins decreased by a modest 1.3 percentage points to 18.3% in FY24 from 19.6% in FY23.
- Net Profit: Net profit in FY24, at ₹5,276 million, declined 6.1% from ₹5,618 million in the corresponding previous year, and net profit margins declined from 9.4% to 7.9%.
- Earnings Per Share (EPS): Basic EPS declined to ₹27.54 in FY24 from ₹29.42 in FY23.
- Debt-to-Equity Ratio: At 0.3 for FY23 and FY24 too, the company has a good financial profile.
Emcure’s steady revenue growth and robust market share underpin its credentials in the pharma space. However, a marginal decline in profitability does indicate areas of potential efficiency gain.
With the expansion of the Arth portfolio and Vidya Balan promoting women’s health, Emcure Pharmaceuticals is poised to drive meaningful conversation and encourage women to take charge of their overall health by embracing holistic, evidence-based approaches.
Read More: India’s pharma sector is booming, with 8% CAGR and 9% export growth in 2024
